Nucleic Acids

Total RNA was prepared from cell line WM165. WM165 is a metastatic human melanoma cell line that displays fibroblastic morphology. This cell line was derived from the same patient as the cell lines WM115, WM266-4, and WM165-1. WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases. This cell line expresses mutant BRAF (V600D), PTEN loss of function including hemizygous deletion, and wild type N-RAS, c-KIT, and CDK4. WM165 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM1716. WM1716 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1716 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM1716. WM1716 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1716 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM1716. WM1716 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1716 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM1716. WM1716 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1716 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM1716. WM1716 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1716 cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM1716. WM1716 is a metastatic human melanoma cell line. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. WM1716 cells produce xenograft tumors when injected into immunocompromised mice.

DNA was prepared from cell line WM1727. WM1727A is a metastatic human melanoma cell line that displays pigmented melanocytic morphology and float easily in culture medium. WM1727A cells produce xenograft tumors when injected into immunocompromised mice. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4.

DNA was prepared from cell line WM1727. WM1727A is a metastatic human melanoma cell line that displays pigmented melanocytic morphology and float easily in culture medium. WM1727A cells produce xenograft tumors when injected into immunocompromised mice. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses PTEN loss of function including hemizygous deletion and is wild type for N-RAS, c-KIT, and CDK4.